|
GB9020075D0
(en)
|
1990-09-14 |
1990-10-24 |
Filler Aaron G |
Contrast agents for magnetic resonance imaging of axonal transport
|
|
US5948384A
(en)
*
|
1990-09-14 |
1999-09-07 |
Syngenix Limited |
Particulate agents
|
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
|
US5827819A
(en)
*
|
1990-11-01 |
1998-10-27 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with neurologically active compounds for targeting
|
|
US6919067B2
(en)
|
1991-09-13 |
2005-07-19 |
Syngenix Limited |
Compositions comprising a tissue glue and therapeutic agents
|
|
DE69328430T2
(en)
*
|
1992-07-27 |
2001-01-25 |
The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer |
TARGETED LIPOSOME TO THE BLOOD BRAIN CABINET
|
|
DE4303646A1
(en)
*
|
1993-02-09 |
1994-08-11 |
Basf Ag |
The use of thrombin inhibitors to combat neurodegenerative diseases
|
|
WO1995007092A1
(en)
*
|
1993-09-10 |
1995-03-16 |
The University Of Medicine And Dentistry Of New Jersey |
Blood-brain barrier transporters of neurological agents
|
|
DE69529054T2
(en)
*
|
1994-02-28 |
2003-08-21 |
Nanopharm Ag |
SYSTEM FOR TARGETED ACTIVE SUBSTANCE, METHOD FOR THE PRODUCTION AND USE THEREOF
|
|
ES2312177T3
(en)
|
1996-05-22 |
2009-02-16 |
Viventia Biotech Inc. |
FRAGMENTS OF UNION TO ANTIGENS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES THAT CODIFY FRAGMENTS AND THE USE OF THE SAME FOR THE PROFILAXIS AND CANCER DETECTION.
|
|
JP2001508648A
(en)
|
1996-11-06 |
2001-07-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Tumor necrosis factor receptor releasing enzyme, composition containing the enzyme, and method of using the same
|
|
US7115722B1
(en)
|
1997-05-22 |
2006-10-03 |
Viventia Biotech, Inc. |
Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
|
|
GB9721901D0
(en)
|
1997-10-16 |
1997-12-17 |
Univ Manchester |
Particles
|
|
WO2002009700A1
(en)
|
2000-07-28 |
2002-02-07 |
Cancer Research Technology Limited |
Cancer treatment by combination therapy
|
|
US8251986B2
(en)
|
2000-08-17 |
2012-08-28 |
Angiodynamics, Inc. |
Method of destroying tissue cells by eletroporation
|
|
US7795232B1
(en)
|
2000-08-25 |
2010-09-14 |
Genta Incorporated |
Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
|
|
PA8536201A1
(en)
|
2000-12-29 |
2002-08-29 |
Kenneth S Warren Inst Inc |
PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
IL158623A0
(en)
|
2001-04-30 |
2004-05-12 |
Symbiontics Inc |
Subcellular targeting of therapeutic proteins
|
|
US7629309B2
(en)
|
2002-05-29 |
2009-12-08 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
US6994706B2
(en)
|
2001-08-13 |
2006-02-07 |
Minnesota Medical Physics, Llc |
Apparatus and method for treatment of benign prostatic hyperplasia
|
|
GB0121285D0
(en)
|
2001-09-03 |
2001-10-24 |
Cancer Res Ventures Ltd |
Anti-cancer combinations
|
|
IL161352A0
(en)
*
|
2001-10-16 |
2004-09-27 |
Symbiontics Inc |
Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
|
|
US20030072761A1
(en)
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
|
GB2386836B
(en)
|
2002-03-22 |
2006-07-26 |
Cancer Res Ventures Ltd |
Anti-cancer combinations
|
|
NZ554740A
(en)
|
2002-05-24 |
2009-01-31 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
|
GB2394658A
(en)
|
2002-11-01 |
2004-05-05 |
Cancer Rec Tech Ltd |
Oral anti-cancer composition
|
|
US7834147B2
(en)
*
|
2003-04-28 |
2010-11-16 |
Childrens Hospital Medical Center |
Saposin C-DOPS: a novel anti-tumor agent
|
|
US7414076B2
(en)
|
2003-06-23 |
2008-08-19 |
Neurochem (International) Limited |
Methods and compositions for treating amyloid-related diseases
|
|
US7244764B2
(en)
|
2003-06-23 |
2007-07-17 |
Neurochem (International) Limited |
Methods and compositions for treating amyloid-related diseases
|
|
JP4738337B2
(en)
|
2003-09-12 |
2011-08-03 |
テルシカ インコーポレーティッド |
Treatment of insulin-like growth factor-1 (IGF-1) deficiency
|
|
WO2005047512A2
(en)
|
2003-11-12 |
2005-05-26 |
Shering Corporation |
Plasmid system for multigene expression
|
|
AR046639A1
(en)
|
2003-11-21 |
2005-12-14 |
Schering Corp |
ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
|
|
EP1716232B9
(en)
|
2004-02-10 |
2010-10-13 |
ZyStor Therapeutics , Inc. |
Acid alpha-glucosidase and fragments thereof
|
|
WO2006060419A2
(en)
|
2004-12-03 |
2006-06-08 |
Schering Corporation |
Biomarkers for pre-selection of patients for anti-igf1r therapy
|
|
CA2592320C
(en)
|
2004-12-22 |
2015-11-24 |
Neurochem (International) Limited |
Methods and compositions for treating amyloid-related diseases
|
|
US9988427B2
(en)
|
2005-05-13 |
2018-06-05 |
Charite Universitaetsmedizen-Berlin |
Erythropoietin variants
|
|
EP2279726A3
(en)
|
2005-05-26 |
2012-06-20 |
Biorest Ltd. |
Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
|
|
EA015672B1
(en)
|
2005-08-05 |
2011-10-31 |
Араим Фармасьютикалз, Инк. |
Tissue protective peptides and uses thereof
|
|
ES2533463T3
(en)
|
2006-10-12 |
2015-04-10 |
Bhi Limited Partnership |
Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
|
|
EP2081956B1
(en)
|
2006-11-13 |
2013-03-20 |
Charité - Universitätsmedizin Berlin |
Method of cell culture and method of treatment comprising a vepo protein variant
|
|
WO2008134828A2
(en)
|
2007-05-04 |
2008-11-13 |
Katholieke Universiteit Leuven |
Tissue degeneration protection
|
|
KR20180041269A
(en)
|
2008-01-22 |
2018-04-23 |
아라임 파마슈티칼즈, 인크. |
Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
|
|
EP2274011A4
(en)
*
|
2008-04-17 |
2013-04-24 |
Banyan Biomarkers Inc |
An antibody bound synthetic vesicle containing active agent molecules
|
|
US10702326B2
(en)
|
2011-07-15 |
2020-07-07 |
Virginia Tech Intellectual Properties, Inc. |
Device and method for electroporation based treatment of stenosis of a tubular body part
|
|
US10238447B2
(en)
|
2008-04-29 |
2019-03-26 |
Virginia Tech Intellectual Properties, Inc. |
System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
|
|
US9198733B2
(en)
|
2008-04-29 |
2015-12-01 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning for electroporation-based therapies
|
|
US11254926B2
(en)
|
2008-04-29 |
2022-02-22 |
Virginia Tech Intellectual Properties, Inc. |
Devices and methods for high frequency electroporation
|
|
US10117707B2
(en)
|
2008-04-29 |
2018-11-06 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
|
|
EP2280741A4
(en)
|
2008-04-29 |
2012-06-13 |
Virginia Tech Intell Prop |
IRREVERSIBLE ELECTROPORATION FOR CREATING TISSUE SCAFFOLDS
|
|
US9867652B2
(en)
|
2008-04-29 |
2018-01-16 |
Virginia Tech Intellectual Properties, Inc. |
Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
|
|
US10245098B2
(en)
|
2008-04-29 |
2019-04-02 |
Virginia Tech Intellectual Properties, Inc. |
Acute blood-brain barrier disruption using electrical energy based therapy
|
|
US9283051B2
(en)
|
2008-04-29 |
2016-03-15 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating a treatment volume for administering electrical-energy based therapies
|
|
US11272979B2
(en)
|
2008-04-29 |
2022-03-15 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
|
|
US8992517B2
(en)
|
2008-04-29 |
2015-03-31 |
Virginia Tech Intellectual Properties Inc. |
Irreversible electroporation to treat aberrant cell masses
|
|
US10272178B2
(en)
|
2008-04-29 |
2019-04-30 |
Virginia Tech Intellectual Properties Inc. |
Methods for blood-brain barrier disruption using electrical energy
|
|
CA2723412A1
(en)
|
2008-05-07 |
2009-11-12 |
Zystor Therapeutics, Inc. |
Lysosomal targeting peptides and uses thereof
|
|
EP2342356A4
(en)
|
2008-09-29 |
2012-11-21 |
Univ Ben Gurion |
BETA-AMYLOID PEPTIDES AND METHODS OF USE THEREFOR
|
|
WO2010108503A1
(en)
|
2009-03-24 |
2010-09-30 |
Life & Brain Gmbh |
Promotion of neuronal integration in neural stem cell grafts
|
|
US8632534B2
(en)
|
2009-04-03 |
2014-01-21 |
Angiodynamics, Inc. |
Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD)
|
|
US11382681B2
(en)
|
2009-04-09 |
2022-07-12 |
Virginia Tech Intellectual Properties, Inc. |
Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
|
|
US11638603B2
(en)
|
2009-04-09 |
2023-05-02 |
Virginia Tech Intellectual Properties, Inc. |
Selective modulation of intracellular effects of cells using pulsed electric fields
|
|
WO2010138919A2
(en)
|
2009-05-28 |
2010-12-02 |
Angiodynamics, Inc. |
System and method for synchronizing energy delivery to the cardiac rhythm
|
|
US9895189B2
(en)
|
2009-06-19 |
2018-02-20 |
Angiodynamics, Inc. |
Methods of sterilization and treating infection using irreversible electroporation
|
|
EP2327725A1
(en)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Anti-C5a binding moieties with high blocking activity
|
|
MX2012006580A
(en)
|
2009-12-11 |
2012-09-28 |
Genecode As |
Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators.
|
|
EP2627274B1
(en)
|
2010-10-13 |
2022-12-14 |
AngioDynamics, Inc. |
System for electrically ablating tissue of a patient
|
|
US20140066439A1
(en)
|
2010-11-10 |
2014-03-06 |
Katholieke Universiteit Leuen, K.U.Leuven R&D |
Osteoclast activity
|
|
WO2012088149A2
(en)
|
2010-12-20 |
2012-06-28 |
Virginia Tech Intellectual Properties, Inc. |
High-frequency electroporation for cancer therapy
|
|
EP3345545B1
(en)
|
2011-04-21 |
2021-10-20 |
The Regents of The University of California |
Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
|
|
CN104125826A
(en)
|
2011-12-22 |
2014-10-29 |
努沃研究有限责任公司 |
Chlorite or chlorate liposome compositions
|
|
US9414881B2
(en)
|
2012-02-08 |
2016-08-16 |
Angiodynamics, Inc. |
System and method for increasing a target zone for electrical ablation
|
|
AU2014228387B2
(en)
|
2013-03-11 |
2016-09-01 |
Sciadonics, Inc. |
Lipid compositions containing bioactive fatty acids
|
|
HK1220606A1
(en)
|
2013-03-11 |
2017-05-12 |
Nobesita As |
Natural lipids containing non-oxidizable fatty acids
|
|
EP3088518A4
(en)
|
2013-12-25 |
2017-09-20 |
JCR Pharmaceuticals Co., Ltd. |
Novel anti-transferrin receptor antibody that passes through blood-brain barrier
|
|
WO2015175570A1
(en)
|
2014-05-12 |
2015-11-19 |
Virginia Tech Intellectual Properties, Inc. |
Selective modulation of intracellular effects of cells using pulsed electric fields
|
|
US12114911B2
(en)
|
2014-08-28 |
2024-10-15 |
Angiodynamics, Inc. |
System and method for ablating a tissue site by electroporation with real-time pulse monitoring
|
|
WO2016100325A1
(en)
|
2014-12-15 |
2016-06-23 |
Virginia Tech Intellectual Properties, Inc. |
Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
|
|
WO2017087685A1
(en)
|
2015-11-20 |
2017-05-26 |
The Regents Of The University Of California |
Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
|
|
US11008402B2
(en)
|
2016-09-15 |
2021-05-18 |
Universitat Stuttgart |
Antigen binding protein against HER3
|
|
WO2018087720A1
(en)
|
2016-11-14 |
2018-05-17 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
|
US10905492B2
(en)
|
2016-11-17 |
2021-02-02 |
Angiodynamics, Inc. |
Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
|
|
US10376595B2
(en)
|
2017-04-03 |
2019-08-13 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of C5a activity
|
|
JP7280624B2
(en)
|
2017-04-03 |
2023-05-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Deformable nanoscale vehicles (DNV) for transblood-brain barrier, transmucosal and transdermal drug delivery
|
|
TWI826364B
(en)
|
2017-04-03 |
2023-12-21 |
德商因夫萊亞斯有限公司 |
Activity
|
|
US20230137562A1
(en)
|
2017-06-07 |
2023-05-04 |
Adrx, Inc. |
Tau aggregation inhibitors
|
|
JP7502865B2
(en)
|
2017-06-23 |
2024-06-19 |
インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Treatment of inflammatory diseases with inhibitors of C5A activity
|
|
AU2018318319A1
(en)
|
2017-08-18 |
2020-02-20 |
Adrx, Inc. |
Tau aggregation peptide inhibitors
|
|
US11607537B2
(en)
|
2017-12-05 |
2023-03-21 |
Virginia Tech Intellectual Properties, Inc. |
Method for treating neurological disorders, including tumors, with electroporation
|
|
US11925405B2
(en)
|
2018-03-13 |
2024-03-12 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning system for immunotherapy enhancement via non-thermal ablation
|
|
US11311329B2
(en)
|
2018-03-13 |
2022-04-26 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
|
|
US12390262B2
(en)
|
2018-03-13 |
2025-08-19 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning system for immunotherapy enhancement via non-thermal ablation
|
|
AU2019337564A1
(en)
|
2018-09-10 |
2021-05-06 |
Cold Spring Harbor Laboratory |
Methods for treating pancreatitis
|
|
US11149009B2
(en)
|
2019-03-11 |
2021-10-19 |
Inflarx Gmbh |
Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor
|
|
US11950835B2
(en)
|
2019-06-28 |
2024-04-09 |
Virginia Tech Intellectual Properties, Inc. |
Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
|
|
US12214189B2
(en)
|
2019-07-24 |
2025-02-04 |
Virginia Tech Intellectual Properties, Inc. |
Fourier analysis spectroscopy for monitoring tissue impedance changes and treatment outcome during electroporation-based-therapies
|
|
KR20220159983A
(en)
|
2020-03-27 |
2022-12-05 |
인플라알엑스 게엠베하 |
Inhibitors of C5a for treatment of coronavirus infection
|
|
US12485279B2
(en)
|
2020-11-25 |
2025-12-02 |
Virginia Tech Intellectual Properties, Inc. |
Methods for modulating temporal infrastructure of pulsed electric fields
|
|
US12180274B2
(en)
|
2023-05-26 |
2024-12-31 |
Inflarx Gmbh |
Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
|
|
WO2025037010A1
(en)
|
2023-08-16 |
2025-02-20 |
Inflarx Gmbh |
Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases
|